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Human  epidermal  growth  factor receptor  (HER)2/neu  kinase  domain  mutations  are  found  in approxi-
mately  1–4%  of  lung  adenocarcinomas  with  a similar  phenotype  to tumors  with  epidermal  growth  factor
receptor  (EGFR)  mutations.  Afatinib  is  a potent  irreversible  ErbB  family  blocker.  We  determined  the
tumor  genomic  status  of the  EGFR  and  HER2  genes  in  non-  or light  smokers  with  lung  adenocarcinoma
in  patients  who  were entered  into  an  exploratory  Phase  II study  with  afatinib.  Five  patients  with  a  non-on-small cell lung cancer (NSCLC)
pidermal growth factor receptor (EGFR)




smoking  history  and  metastatic  lung  adenocarcinomas  bearing  mutations  in the  kinase  domain  of  HER2
gene  were  identiﬁed,  three  of which  were  evaluable  for  response.  Objective  response  was  observed  in
all three  patients,  even  after  failure  of  other  EGFR-  and/or  HER2-targeted  treatments;  the  case  histories
of  these  patients  are  described  in  this  report.  These  ﬁndings  suggest  that  afatinib  is a potential  novel
treatment  option  for this  subgroup  of  patients,  even  when  other  EGFR  and  HER2  targeting  treatments
have  failed.utation
. Introduction
The presence of activating mutations in the tyrosine kinase
omain of the human epidermal growth factor receptor 1
EGFR/HER1/erbB1) in non-small cell lung cancer (NSCLC) cor-
elates with a clinical phenotype of adenocarcinoma in never
r light smokers, and renders the tumor exquisitely sensitive to
GFR tyrosine kinase inhibitors (TKIs) [1–3]. The introduction of
argeted drugs for the treatment of NSCLC with EGFR-directed
mall-molecule TKIs [3] and monoclonal antibodies [4] has led
o a signiﬁcant but relatively small overall improvement in clini-
al outcome of unselected patients with advanced disease. EGFR
utations and increased EGFR copy number by ﬂuorescence
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in situ hybridization (FISH) are predictive biomarkers that identify
patients who  are most sensitive to TKIs [5,6].
HER2 kinase domain mutations are rare in NSCLC, and are found
in approximately 1–4% of lung adenocarcinomas with a similar phe-
notype as tumors with EGFR mutations [7–9]. In 229 patients with
adenocarcinoma of the lung, with a little or no smoking history, we
identiﬁed a HER2 mutation in the tumor tissue of ﬁve patients (2%),
which is 10-fold rarer than the frequency of EGFR mutations in the
same cohort of patients [10]. In other cohorts with potentially dif-
fering phenotypic selection criteria, the HER2 mutation rate was
even lower: in tumors from 830 patients analyzed within the NCI’s
Lung Cancer Mutation Consortium (LCMC) [11] a HER2 mutation
was found in only three cases (1%) compared to 98 cases with an
EGFR mutation. In 552 samples analyzed at Massachusetts General
Hospital, only one patient with a HER2 mutation was identiﬁed
[12]. The HER2 mutations found in clinical samples so far are all in
exon 20.
Afatinib is a potent, irreversible ErbB family blocker with pre-
clinical activity in Ba/F3 cells expressing an artiﬁcial HER2 mutant
and in a human lung cancer cell line with an insertional mutation
at codon 776 [13].
We  determined the tumor genomic status of the EGFR and
Open access under CC BY-NC-ND license.HER2 genes in non- or light smokers with lung adenocarcinoma
by denaturing gradient gel electrophoresis (DGGE)/DNA sequenc-
ing of NSCLC tumor tissue or increased copy number of the EGFR
gene, as determined by FISH analysis. HER2 FISH was not required









































gFig. 1. Examples of 
or entry into the study and therefore not systematically under-
aken. In Case 2, HER2 FISH was performed long before inclusion
nto the current study. Patients were entered into this exploratory
hase II study with afatinib, which, among others, included a cohort
f patients with HER2 kinase domain mutations [14]. There were
o restrictions in prior therapy for patients with HER2 mutations,
lthough patients had to have at least one measurable tumor lesion
hat could be accurately measured by computed tomography (CT)
can or magnetic resonance imaging [14]. Here, we report the ﬁrst
herapeutic activity of afatinib in three patients with lung adeno-
arcinoma and a non-smoking history, whose tumors exhibited
ctivating HER2 mutations in exon 20 (Fig. 1). Treatment with
fatinib resulted in an objective remission in all three patients,
ven after failure of other EGFR- and/or HER2-targeted treatments.
ollowing disease progression, there was an option to combine a
ower level of afatinib with weekly paclitaxel at 80 mg/m2 on a
/4-week schedule. Five patients were treated in this study; two
atients were not evaluable due to early treatment discontinuation.
he study was approved by the Ethical Committee of the Univer-
itair Ziekenhuis Brussel and participating centers and patients
rovided informed consent. Here we report on three evaluable
atients.
. Case 1
A 72-year-old, non-smoking female was diagnosed with a stage
II lung adenocarcinoma (right lower lobe) in May  2007. Treat-
ent with four cycles of carboplatin/gemcitabine resulted in a
artial remission. Following progressive disease (PD) in January
008, administration of an additional four cycles of reduced dose
arboplatin/gemcitabine resulted in stable disease (SD). In May
008, the patient was found to have PD in the lung, with symp-
oms of mildly productive cough. An exon 20 HER2 mutation
p.Tyr772 Ala775dup; Fig. 1) was found in the tumor DNA extracted
rom the original diagnostic biopsy in May  2007.
Treatment with afatinib (50 mg/day) started in July 2008. After 8
ays, positron emission tomography-CT (PET-CT) imaging showed
 radiological partial response (PR) and a metabolic complete
esponse that was maintained for 3 months (Fig. 2A). Treatment
as interrupted three times due to side effects (diarrhea, dysgeu-ia and skin adverse events [AEs]; all Common Terminology Criteria
or Adverse Events [CTCAE] Grade 2) and prompted successive dose
eductions to 30 mg/day. The patient was deemed to have pro-
ression after 3 months based on an approximate 20% increase inexon 20 mutations.
target lesions above the nadir, although the total tumor burden was
below baseline and the patient continued to receive monotherapy
with afatinib. Following further progression in May  2009, afatinib
was combined with paclitaxel, but the patient showed progression
solely due to the occurrence of brain metastases shortly afterwards
and died one month after going off study without having received
any subsequent therapy. The patient was treated with afatinib for
a total of 9 months and survived one year from study entry.
3. Case 2
A 62-year-old, non-smoking female with adenocarcinoma of the
right lung was initially diagnosed in 2002. Her tumor cells had
increased EGFR/HER1 copy number, as assessed by FISH, as well
as mutations in the EGFR kinase domain (exon 21: p.Ala859Thr)
and in HER2 (exon 20: p.Gly776Leu). She underwent a lobectomy
for a pT2N1 adenocarcinoma and received adjuvant chemotherapy
with cisplatin/gemcitabine, followed by radiotherapy. A relapse in
the lung and mediastinal lymph nodes in July 2003 was  treated
with four cycles of the same chemotherapy, resulting in SD. From
2004 through 2008, PD was treated sequentially with docetaxel
(six cycles; SD), geﬁtinib (PD), trastuzumab with paclitaxel (PR),
lapatinib, gemcitabine and vinorelbine.
At inclusion in the current study, this patient suffered from dys-
pnea and retrosternal and right chest wall pain requiring narcotic
pain relief, as well as facial and cervical soft-tissue congestion. Her
Eastern Cooperative Oncology Group (ECOG) performance status
(PS) was 2.
From July 2008, this patient was treated with afatinib
(50 mg/day). Within 2 weeks, the cervical soft-tissue swelling
decreased with marked improvement in her general condition
(ECOG PS: 1). On Day 15, a metabolic response was  observed
in a PET-CT scan (Fig. 2B). Treatment-related AEs included skin
reactions, diarrhea, intermittent nausea and vomiting, pyrosis and
epigastric pain, fatigue, mucositis, sialorrhea, hair thinning, nail
changes and ﬁssures of the nail bed and ﬁngertip. After 2 months of
treatment (August 2008), a PR was observed by CT scan. Treatment
was interrupted due to the associated diarrhea, and the dose was
reduced successively to 40 mg/day and 30 mg/day (October 2008).
At that time, the patient was  progressive compared to the nadir
of response, but still had a tumor burden reduction (20% decrease
in target lesions) by CT scan, compared to baseline. The time to
progression on single-agent afatinib was 4 months; in December
2008, she developed further PD in the liver and mediastinal lymph
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Fig. 2. (A) Case 1 – response to single-agent afatinib. Panels A1 and A3 are the baseline PET-CT and CT scans, respectively. Panels A2 and A4 are the post-treatment PET-CT and
CT  scans showing the early response to afatinib. (B) Case 2 – response to single-agent afatinib. Panel B1 is a baseline PET-CT image. Panels B2 and B3 are the post-treatment
PET-CT  scans showing metabolic response on Day 15 of treatment and partial remission after 2 months, with disease progression at 4 months (Panel B4). (C) Case 3 – response
to  single-agent afatinib and in combination with paclitaxel. Panel C1 is a baseline PET-CT image, panel C2 shows the important response in pleural and liver disease. Panel
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odes. Weekly paclitaxel was added and the dose of afatinib was
educed to 20 mg.  The patient had SD overall, but with a metabolic
nd radiological response in the liver for 9 months until April 2009,
fter which she progressed. The time to progression after paclitaxel
as added to afatinib was 4 months. The patient died in September
009, a total of 14 months from study entry.
. Case 3
In March 2006, a 49-year-old Caucasian, non-smoking woman
as diagnosed with stage IV right upper-lobe lung adenocarcinoma
ith diffuse pleural, liver and soft-tissue metastases. The tumor
ells had an increased EGFR gene copy number, as assessed by
ISH, with a wild-type sequence. This patient received ﬁrst-line
reatment with erlotinib at 150 mg/day, but clinical and radiolog-
cal progression occurred within 3 months. From June 2006, she
as treated with cisplatin/gemcitabine, with an objective tumor
esponse, but treatment was interrupted due to cumulative toxic-
ty. She then received, sequentially, gemcitabine (PD), carboplatin
transient response, but hematological intolerance), vinorelbine
PD), pemetrexed (transient response) and weekly cisplatin (symp-
omatic and objective response; treatment stopped because of
ntolerance). Additional genomic analysis revealed an insertional
uplication (p.Gly778 Pro780dup) in exon 20 of the HER2 gene
Fig. 1). At inclusion in the current study in June 2008 [14], the
atient was severely symptomatic, with pain in the right chest,
ight hypochondrium and right shoulder, and anorexia and fatigue.
he had also developed asymptomatic bone metastases and had an
COG PS of 1.
Within 2 weeks of starting afatinib (50 mg/day), the patient
ad a rapid clinical and symptomatic response, with disappear-
nce of all disease-related symptoms, as well as overall SD with
 radiological response in liver and pleura, which was maintained
or 3 months (Fig. 2C). Treatment with afatinib (50 mg/day) was
ssociated with skin-related AEs, diarrhea and mucosal inﬂam-
ation with intermittent epistaxis, aphthous stomatitis and dry
yes.
The time to progression on single-agent afatinib was 4 months;
ollowing PD in October 2008, the patient received afatinib
40 mg/day) combined with weekly paclitaxel (80 mg/m2). After
ne cycle, disease-related symptoms disappeared and a dramatic
artial remission was seen. As of July 2009, this patient had an ECOG
S of 0, a disease volume of less than that at her remission after
rst-line cisplatin-based chemotherapy 2.5 years earlier (Fig. 2C).
ustained control of carcinoembryonic antigen (CEA) tumor marker
evels was also achieved during afatinib treatment. There was  an
ncrease in CEA levels during ineffective prior chemotherapy treat-
ent and CEA levels declined rapidly to normal after combination
f afatinib and weekly paclitaxel. Afatinib treatment was continued
or a total of 15 months, 11 of which were in combination with pacli-
axel, after which time the patient developed a brain metastasis
ithout concurrent progression at the other disease sites. Adverse
vents with afatinib and weekly paclitaxel were mild and included
kin reaction, diarrhea, fatigue and hematological AEs.
After going off study in September 2009, the patient received
rastuzumab sequentially combined with weekly paclitaxel for 6
onths (CEA marker stabilization for 3 months), liposomal dox-
rubicin for 4 months (marker stabilization for 2 months), weekly
isplatin for three administrations, and oral etoposide for 3 months
ith no further clinical beneﬁt. In addition, she developed lep-
omeningeal disease in June 2010, which was treated with four
ntrathecal administrations of depocyte leading to a durable com-
lete cytological and symptomatic response of her leptomeningeal
isease. The patient died in March 2011, with an overall survival of
2 months after inclusion in the study.er 76 (2012) 123– 127
5. Additional cases
Two other patients with HER2 mutations were enrolled into the
study, but both cases were considered to be non-evaluable. One
patient was a 51-year-old woman  with a 4 pack-year smoking his-
tory (who stopped smoking 29 years before study entry). She was
treated with afatinib monotherapy for 7 weeks and discontinued
treatment due to the occurrence of Grade 3 rash. Stable disease
was observed at this time. The patient received subsequent peme-
trexed therapy with disease progression after two cycles, followed
by docetaxel with disease stabilization for 5 months, after which
the patient was lost to follow-up.
The second patient was  a 62-year-old female, never smoker,
who received afatinib for only 2 weeks and was discontinued due
to Grade 3 diarrhea and deterioration of her general condition. No
tumor assessments were undertaken within the study after base-
line. The patient was  subsequently lost to follow-up.
6. Discussion
We  describe the ﬁrst evidence of clinical beneﬁt from treat-
ment with afatinib in patients with an exon 20 HER2-mutant lung
adenocarcinoma who have previously failed various chemother-
apy regimens and the EGFR and/or HER2 inhibitors erlotinib,
trastuzumab and lapatinib. Five patients were identiﬁed with a
HER2 mutation, although only three were evaluable for response;
mutations in all three patients were in exon 20 (two insertional
duplications and one single amino-acid mutation). Analogous
mutations in EGFR in exon 20 are relatively insensitive to inhibi-
tion by the reversible inhibitor geﬁtinib [15]. In two  patients, a rapid
metabolic response was  observed within 1–2 weeks. Two  patients
had genomic activation of both EGFR and HER2.
The most striking response to single-agent afatinib was
observed in Case 1, with a p.Tyr772 Ala775dup mutation in
HER2. Compared with the other two patients, this patient showed
genomic activation of HER2 only. This mutation causes an amino
acid change identical to a mutation studied in a recently pub-
lished preclinical model of mutant HER2-driven lung cancer [16].
In this mouse model, the forced expression of the mutant allele
is capable of inducing invasive adenosquamous carcinomas that
are restricted to the proximal and distal bronchioles. These cancers
were completely dependent on the presence of this mutation and
regressed completely when the expression of the mutant gene was
reversed. Treatment with afatinib led to signiﬁcant tumor regres-
sion in this preclinical model. In two  of our clinical cases, the
addition of paclitaxel to afatinib led to additional disease control,
with prolonged remission in one patient despite a short response
to single-agent afatinib, raising the possibility of synergism. In a
xenograft of the HER2 mutant lung cancer cell line H1781, which
contains a homozygous single amino-acid insertion in exon 20 [8],
administration of afatinib resulted in disease stabilization, in con-
trast to the tumor regression observed in the preclinical mouse
model. Taken together with our clinical experience, this indicates
that the human HER2-driven lung cancer may  have a more complex
molecular pathogenesis than the preclinical HER2-driven mouse
model.
The therapeutic effect observed in Case 2 was also of consid-
erable interest, as the tumor showed genomic activation of both
EGFR and HER2, and was  previously treated with, and had become
clinically resistant to, erlotinib, trastuzumab and lapatinib [17].Although we  cannot exclude that the second response, with
added paclitaxel, results from the activity of single-agent pacli-
taxel, the magnitude and duration of the response in patients with





















































factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer
using PF-00299804 and trastuzumab. J Clin Oncol 2010;28:e507–10.J. De Grève et al. / Lung
he response was to some extent achieved by the combination of
fatinib with paclitaxel.
A limited number of studies in NSCLC have attempted to
valuate the activity of HER2-targeting agents, and have been
ummarized by Kelly et al. [18]. These studies could not reveal a
igniﬁcant beneﬁt from trastuzumab or lapatinib. However, these
tudies were performed in NSCLC patient populations unselected
or HER2 status (HER2 copy number or mutation) and primarily
n combination with chemotherapeutic agents, and therefore were
ot apt to detect clinical beneﬁt in patients with a genomic acti-
ation of HER2. There was, however, a report of one patient with
 HER2 FISH positive tumor, but no HER2 or EGFR mutation, who
chieved a short-lived response (4 weeks) to a pan-HER inhibitor
dacomitinib; PF-00299804) and subsequently progressed follow-
ng additional treatment with trastuzumab, but who responded
fter vinorelbine was added. Furthermore, an additional patient
ith a HER2 mutation responded to trastuzumab plus vinorelbine
fter failure of platinum-based chemotherapy and geﬁtinib. How-
ver, this case does not allow for the assessment of the independent
ctivity of trastuzumab [19].
This report suggests that the presence of HER2 mutations may
haracterize a subgroup of NSCLC that is constitutively dependent
n the HER2 pathway. Afatinib is a potential novel treatment option
or this subgroup of patients, even when other EGFR and HER2 tar-
eting treatments have failed. The rate and duration of response
ssociated with afatinib and the combined activity of afatinib and
aclitaxel should be further assessed in earlier lines of treatment
n this genomically deﬁned population.
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